Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study
Abstract The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Rheumatology international - 38(2017), 4 vom: 01. Dez., Seite 623-630 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goel, Ruchika [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2017 |
|---|
| doi: |
10.1007/s00296-017-3881-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2044927063 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2044927063 | ||
| 003 | DE-627 | ||
| 005 | 20230331101852.0 | ||
| 007 | tu | ||
| 008 | 200819s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-017-3881-4 |2 doi | |
| 035 | |a (DE-627)OLC2044927063 | ||
| 035 | |a (DE-He213)s00296-017-3881-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Goel, Ruchika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2017 | ||
| 520 | |a Abstract The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications. | ||
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a MRP 8/14 | |
| 650 | 4 | |a Calprotectin | |
| 650 | 4 | |a Vasculitis | |
| 650 | 4 | |a Biomarker | |
| 700 | 1 | |a Nair, Aswin |4 aut | |
| 700 | 1 | |a Kabeerdoss, Jayakanthan |4 aut | |
| 700 | 1 | |a Mohan, Hindhumathi |4 aut | |
| 700 | 1 | |a Jeyaseelan, Visalakshi |4 aut | |
| 700 | 1 | |a Joseph, George |4 aut | |
| 700 | 1 | |a Danda, Debashish |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 38(2017), 4 vom: 01. Dez., Seite 623-630 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2017 |g number:4 |g day:01 |g month:12 |g pages:623-630 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00296-017-3881-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2017 |e 4 |b 01 |c 12 |h 623-630 | ||